Form 4: Corbus Pharmaceuticals Director John Jenkins Acquires Restricted Stock Units

Director John Jenkins received 2,783 restricted stock units (RSUs) in Corbus Pharmaceuticals Holdings, Inc., which will vest in one year.

Summary

• On May 30, 2024, John Jenkins, a director of Corbus Pharmaceuticals Holdings, Inc., was granted 2,783 restricted stock units (RSUs).
• These RSUs will vest 100% on the one-year anniversary of the grant date.
• Following the transaction, Jenkins beneficially owns a total of 2,816 shares, including the unvested RSUs.
• A Power of Attorney was executed on March 8, 2024, authorizing Yuval Cohen, Sean Moran, and Meghan Houghton to act on behalf of John Jenkins for SEC filings related to Corbus Pharmaceuticals Holdings, Inc.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to insider transactions, which is neutral in sentiment. The grant of RSUs can be seen as a positive sign, aligning director interests with shareholders, but it's a routine event.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, potentially incentivizing positive performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and compliance with securities regulations.

Stakeholder Impact

• The grant of RSUs to a director can positively impact shareholders by aligning management's interests with theirs.

Key Dates